hrqol and pain outcomes in mcrpc: abi ala vs abi pbo in propel
Published 1 year ago • 72 plays • Length 1:27Download video MP4
Download video MP3
Similar videos
-
1:15
magnitude: hrqol in patients with mcrpc receiving niraparib and abiraterone
-
0:44
propel: gene-by-gene efficacy of olaparib and abiraterone in mcrpc
-
0:51
propel: analysis of drug interactions between olaparib abiraterone as 1l therapy in mcrpc
-
4:56
fred saad, esmo 2022: phase iii propel trial of abiraterone olaparib in prostate cancer
-
1:45
the propel clinical trial exploring olaparib plus abiraterone in mcrpc
-
6:41
esmo expert report on combination therapy in advanced prostate cancer @ asco gu 2022
-
0:46
ctc hoxb13 rna in mcrpc: abiraterone/enzalutamide impact
-
3:47
elucidating hrrm status in patients with mcrpc in the propel trial
-
9:23
drs. armstrong, wallis on ai biomarkers and hrqol for localized prostate cancer, mcrpc
-
0:54
convincing long-term survival with abiraterone in mcrpc
-
3:07
propel: olaparib plus abiraterone as 1l treatment for metastatic crpc
-
5:36
propel trial
-
2:26
charles ryan, md: the efficacy of abiraterone plus prednisone in an elderly patient population
-
0:45
dr. hahn on patients with prostate cancer whom neither docetaxel or abiraterone is an option
-
0:31
unmet needs in the use of circulating tumor cells for prostate cancer
-
1:12
dr. pal on sequencing abiraterone and enzalutamide in mcrpc
-
0:56
dr. charles j. ryan on patients with mcrpc treated with abiraterone
-
1:52
treatment sequencing in mcrpc: cabazitaxel vs. abiraterone or enzalutamide
-
1:20
panther: apalutamide abiraterone in black and white mcrpc patients